Skip to main
ETON
ETON logo

ETON Stock Forecast & Price Target

ETON Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eton Pharmaceuticals Inc. is poised for significant revenue growth, with projected Khindivi-related revenues estimated to increase from $3 million in 2025 to a peak of $28 million by 2030. The company's management has demonstrated strong commercial execution, leading to a raised probability of launch for Khindivi to 100% and an anticipated launch date moved up to June. Additionally, the potential for increased market penetration, projected to rise from 40% to 60%, underscores the company's capability to meet unmet patient needs and reinforces a positive outlook for future financial performance.

Bears say

The financial analysis indicates a cautious outlook on Eton Pharmaceuticals due to the reliance on a high discount rate of 11%, which typically suggests increased risk and uncertainty regarding future cash flows. Additionally, the low terminal growth rate of 2% raises concerns about the company's long-term revenue potential, limiting growth expectations beyond the near term. These factors contribute to a relatively modest adjustment in the company's price target, reflecting underlying skepticism about Eton Pharmaceuticals's ability to significantly enhance shareholder value in the near future.

ETON has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eton Pharmaceuticals Inc (ETON) Forecast

Analysts have given ETON a Strong Buy based on their latest research and market trends.

According to 3 analysts, ETON has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eton Pharmaceuticals Inc (ETON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.